NCT07528417Not yet recruitingPhase 2
Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)
Evaluation of Antibiotic Prophylaxis Among Outpatients With Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Multicenter Pilot Trial
Source: ClinicalTrials.gov · Last updated 29 Jun 2026
Brief summary (registry, in English)
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life-changing blood cancers. Patients with MDS and AML commonly experience complications related to infection, which affect patient quality-of-life and can sometimes lead to hospitalization or death. The investigators will conduct a randomized controlled trial to evaluate the effectiveness and safety of levofloxacin (antibiotic) in MDS and AML patients to safely reduce the risk of infection. In this study 50% of patients will be randomized (like a flip of a coin) to receive levofloxacin and the other 50% will receive usual care (control). The primary objective of the trial is to demonstrate the feasibility of a pragmatic pilot trial necessary to inform our planned phase 3 trial. Additionally, the investigators will monitor both groups of patients to see if the investigators improve the risk and/or severity of infection. Levofloxacin is commonly used in other clinical settings but has not been studied in patients with MDS or AML receiving outpatient chemotherapy (ie, chemotherapy that can be given from clinic, rather than a hospital).
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- First submitted
- 7 Apr 2026
- Start date
- Sept 2026
- Primary completion date
- Apr 2028
- Lead sponsor
- University of Manitoba
- NCT number
- NCT07528417
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 75
- From Sept 2026 to the primary completion date, Apr 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Fever/infection within 1 month of chemotherapy initiation
- C-difficile infection within 12 months of chemotherapy initiation
- Known sensitivity/allergy to fluoroquinolones
- History of tendon disorders related to fluoroquinolone administration
- Seizure disorder
Other
- Master platform exclusion criteria:
- Participant is deemed unlikely to survive \>30 days (as determined by clinical team)
- Participant unable to provide informed consent
- MYELO-CAN ABX exclusion criteria:
- Myasthenia gravis
- Pregnancy and/or breastfeeding
Who the study is looking for
- Master platform inclusion criteria:
- Age ≥ 18 years
- Diagnosis of myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm, or acute myeloid leukemia
- MYELO-CAN ABX inclusion criteria:
- 1\. Initiation of hypomethylating agent-based chemotherapy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CancerCare Manitoba Coordinator of this site? Confirm its status | Winnipeg | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.